MenACWY-TT (GSK134612)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MenACWY-TT (GSK134612), covering 2021-10-05 to 2021-10-05. Get the full timeline:
Most recent: Clinical Trial Update: Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine [Phase 3]